Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Durata Prices IPO Of 7.5 Mln Shares At $9.00/shr, Before Underwriting Discounts

RELATED NEWS
Trade DRTX now with 

Durata Therapeutics (DRTX: Quote) announced the pricing of its initial public offering of 7.5 million shares of common stock at a public offering price of $9.00 per share, before underwriting discounts.

The shares are scheduled to commence trading on the NASDAQ Global Market on July 19, 2012 under the ticker symbol "DRTX", noted the company.

Durata further stated that the underwriters have an option for a period of 30 days to buy up to an additional 1.13 million shares of common stock from the company at the public offering price, less the underwriting discount. The offering is expected to close on or about July 24, 2012.

Click here to receive FREE breaking news email alerts for Durata Therapeutics and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Toyota Motor Corp. (TM, TYT.L) Thursday announced 1.1 percent decline in worldwide production for October, as there was a sharp decline in production of passenger cars in Japan. Production outside Japan improved 2.3 percent. In a separate announcement, the Japanese automaker said it will recall more... Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.